Rodel Banal, MD
Pulmonary Disease · Melbourne, FLNPI 1932422433
Payments from drug & device makers
Across 68 payments — averaging $107.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Pulmonx Corporation$1K
- Actelion Pharmaceuticals US, Inc.$676
- Veran Medical Technologies, Inc.$283
- Boehringer Ingelheim$161
- Philips North America LLC$124
- plus $972 from 21 others
What the payments were for
- Travel & lodging$1,99727%
- Food & beverage$2,28231%
- Education$3,01341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,906 |
| Pulmonx Corporation | 5 | $1,170 |
| Actelion Pharmaceuticals US, Inc. | 5 | $676 |
| Veran Medical Technologies, Inc. | 2 | $283 |
| Boehringer Ingelheim | 3 | $161 |
| Philips North America LLC | 4 | $124 |
| Insmed, Inc. | 7 | $116 |
| GSK | 5 | $99 |
| Olympus America Inc. | 1 | $86 |
| Abiomed | 1 | $66 |
| Penumbra, Inc. | 1 | $65 |
| AstraZeneca | 3 | $64 |
| Sanofi | 2 | $56 |
| Electromed, Inc. | 3 | $53 |
| Harmony Biosciences LLC | 1 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 3 | $38 |
| Inogen, Inc. | 2 | $31 |
| Verona Pharma, Inc. | 2 | $31 |
| Fisher & Paykel Healthcare Inc | 2 | $30 |
| United Therapeutics Corporation | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Resmed Corp | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- ZEPHYR ENDOBRONCHIAL VALVE$1,098
- PULMONX CHARTIS TABLET CONSOLE$1,098
- CHARTIS CATHETER$1,098
- ZEPHYR DELIVERY CATHETER$1,098
- Da Vinci Surgical System$864
- UPTRAVI$545
- OPSUMIT$545
- Spin$280
How this compares
$7,292 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 14 | $187,454 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $109,851 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $28,994 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $19,474 |
| Pirfenidone | 12 | $18,392 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,942 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,813 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $9,552 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $8,602 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $6,556 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,988 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $3,411 |
| Montelukast Sodium | 68 | $1,239 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,012 |
| Roflumilast | 11 | $414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $161 | $210,94947 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $99 | $147,126201 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $64 | $37,59652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Melbourne
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.